TScan Reports Q1 Revenue of $982,000, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy TCRX?
Reports Q1 revenue $982,000, consensus $2.5M. "2026 will be a critical year for TScan as we advance our mission to deliver transformative T cell therapies to patients. We have multiple key milestones on the horizon, anchored around the planned initiation of our Phase 3 study of TSC-101 in patients with AML and MDS undergoing allogenic hematopoietic cell transplantation," said Gavin MacBeath, Chief Executive Officer. "We look forward to sharing initial data from Cohort C of our Phase 1 ALLOHA trial, where we have enrolled and treated over 10 patients with our commercial-ready manufacturing process. The robust enrollment in this cohort underscores strong physician support, providing us greater conviction as we prepare to launch the pivotal study."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TCRX
Wall Street analysts forecast TCRX stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.180
Low
3.00
Averages
5.50
High
7.00
Current: 1.180
Low
3.00
Averages
5.50
High
7.00
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TScan Therapeutics Q1 Earnings Miss Expectations
- Disappointing Earnings: TScan Therapeutics reported a Q1 GAAP EPS of -$0.22, missing expectations by $0.01, indicating ongoing challenges in profitability for the company.
- Significant Revenue Decline: The company generated $1M in revenue for the first quarter, a 54.5% year-over-year decrease, falling short of the expected $1.5M, reflecting weak market demand and insufficient sales strategies.
- Stable Cash Position: As of March 31, 2026, TScan's cash and cash equivalents stood at $128.1 million, excluding $5.0 million in restricted cash, indicating relative stability in its financial resources.
- Sufficient Funding Outlook: TScan believes its existing cash resources will be adequate to fund its operating plan into the second half of 2027, suggesting that the company will not face immediate liquidity risks.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
TScan Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: TScan Therapeutics reported a Q4 GAAP EPS of -$0.18, beating market expectations by $0.06, indicating a positive trend in the company's profitability improvement.
- Significant Revenue Growth: The company achieved Q4 revenue of $2.57 million, representing a 283.6% year-over-year increase, which not only surpassed expectations by $0.15 million but also reflects strong demand for its products and improved market acceptance.
- Positive Market Reaction: The market reacted positively to the earnings report exceeding expectations, which may drive the stock price up, enhancing investor confidence and attracting more capital inflow.
- Optimistic Future Outlook: With ongoing R&D and market expansion efforts, the company is expected to continue achieving revenue growth in the coming quarters, further solidifying its competitive position in the biopharmaceutical sector.
See More
TScan Completes Enrollment in ALLOHA™ Trial Cohort C
- Trial Enrollment Completion: TScan Therapeutics announced the completion of enrollment in Cohort C of the ALLOHA™ trial, with over 10 patients treated using the new commercial-ready manufacturing process, which is expected to significantly enhance treatment outcomes and lay the groundwork for subsequent clinical data sharing.
- FDA IND Approval: The company received FDA clearance for IND applications for TSC-102-A01 and TSC-102-A03 targeting patients with HLA types A01:01 and A03:01, respectively, which is anticipated to nearly double the addressable U.S. patient population for its therapies.
- Future Research Plans: TScan plans to initiate Phase 1 trials for both TSC-102 candidates in the second half of 2026, aiming to assess their safety and initial efficacy, thereby advancing the company's strategic positioning in the hematologic malignancies sector.
- Key Data Sharing: The company is set to share safety and early chimerism data from Cohort C in the second quarter of 2026, which is expected to provide a foundation for the pivotal study of TSC-101 and facilitate market expansion in acute myeloid leukemia and myelodysplastic syndromes.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Advancement: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating potential efficacy against resistant blood cancers, with further results expected in Q1 2026.
- Safety Confirmation: Six patients across Cohorts 1, 2, and 3 have successfully completed treatment with GTB-3650, establishing the therapy's safety profile at escalating doses without any dose-limiting toxicities, thereby enhancing confidence in the clinical trial.
- Dose Escalation Plan: The trial is designed to include seven cohorts, with plans to enroll two patients per cohort, escalating doses from 1.25μg/kg/day to potentially 100μg/kg/day, demonstrating the company's ongoing commitment to efficacy and patient care.
- Therapeutic Prospects: GT Biopharma is also advancing GTB-5550, with regulatory submission for human trials expected in late December 2025 or January 2026, further expanding its market opportunities in cancer treatment.
See More
TScan Therapeutics Q1 Earnings Miss Expectations
- Disappointing Earnings: TScan Therapeutics reported a Q1 GAAP EPS of -$0.22, missing expectations by $0.01, indicating ongoing challenges in profitability for the company.
- Significant Revenue Decline: The company generated $1M in revenue for the first quarter, a 54.5% year-over-year decrease, falling short of the expected $1.5M, reflecting weak market demand and insufficient sales strategies.
- Stable Cash Position: As of March 31, 2026, TScan's cash and cash equivalents stood at $128.1 million, excluding $5.0 million in restricted cash, indicating relative stability in its financial resources.
- Sufficient Funding Outlook: TScan believes its existing cash resources will be adequate to fund its operating plan into the second half of 2027, suggesting that the company will not face immediate liquidity risks.
See More
Global Oncology Market Set for Rapid Growth
- Market Size Forecast: The global oncology market is projected to reach $279.98 billion in 2026 and grow to $748.17 billion by 2035, indicating a structural shift from single-agent treatments to combination therapies and next-generation cell therapies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to expand from $65.22 billion in 2025 to $170.19 billion by 2032, as approvals of combination therapies convert previously resistant tumors into viable treatment targets, driving market demand.
- Oncolytics Biotech New Data: Oncolytics Biotech will present new data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can make tumors more susceptible to immunotherapy, particularly showing positive results in breast and gastrointestinal cancer trials.
- Clinical Trial Progress: Oncolytics' REO 033 trial demonstrated a total survival of 27 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, with the FDA granting Fast Track Designation, which is expected to enhance the company's position in high-value markets.
See More
Global Oncology Market Expected to Reach $748.17 Billion
- Market Growth Potential: The global oncology market is valued at $279.98 billion in 2026 and is projected to reach $748.17 billion by 2035, indicating a strong trend towards a shift from single-agent treatments to combination platforms and next-generation cell therapies, potentially creating significant market opportunities for related companies.
- Immuno-Oncology Expansion: The immuno-oncology segment is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, as the approval of combination therapies transforms previously resistant tumors into viable treatment targets, driving rapid industry growth.
- Oncolytics Biotech New Data: Oncolytics Biotech is set to present new mechanistic and translational data at the 2026 American Association for Cancer Research Annual Meeting, indicating that its lead drug pelareorep can enhance tumor sensitivity to immunotherapy, potentially providing crucial scientific support for the company in a competitive market.
- Clinical Trial Progress: Oncolytics' REO 033 trial for KRAS-mutant metastatic colorectal cancer shows an overall survival of 27 months and a 33% objective response rate, with the FDA granting Fast Track Designation, which is expected to create significant market opportunities for the company.
See More
TScan Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: TScan Therapeutics reported a Q4 GAAP EPS of -$0.18, beating market expectations by $0.06, indicating a positive trend in the company's profitability improvement.
- Significant Revenue Growth: The company achieved Q4 revenue of $2.57 million, representing a 283.6% year-over-year increase, which not only surpassed expectations by $0.15 million but also reflects strong demand for its products and improved market acceptance.
- Positive Market Reaction: The market reacted positively to the earnings report exceeding expectations, which may drive the stock price up, enhancing investor confidence and attracting more capital inflow.
- Optimistic Future Outlook: With ongoing R&D and market expansion efforts, the company is expected to continue achieving revenue growth in the coming quarters, further solidifying its competitive position in the biopharmaceutical sector.
See More
TScan Completes Enrollment in ALLOHA™ Trial Cohort C
- Trial Enrollment Completion: TScan Therapeutics announced the completion of enrollment in Cohort C of the ALLOHA™ trial, with over 10 patients treated using the new commercial-ready manufacturing process, which is expected to significantly enhance treatment outcomes and lay the groundwork for subsequent clinical data sharing.
- FDA IND Approval: The company received FDA clearance for IND applications for TSC-102-A01 and TSC-102-A03 targeting patients with HLA types A01:01 and A03:01, respectively, which is anticipated to nearly double the addressable U.S. patient population for its therapies.
- Future Research Plans: TScan plans to initiate Phase 1 trials for both TSC-102 candidates in the second half of 2026, aiming to assess their safety and initial efficacy, thereby advancing the company's strategic positioning in the hematologic malignancies sector.
- Key Data Sharing: The company is set to share safety and early chimerism data from Cohort C in the second quarter of 2026, which is expected to provide a foundation for the pivotal study of TSC-101 and facilitate market expansion in acute myeloid leukemia and myelodysplastic syndromes.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Advancement: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating potential efficacy against resistant blood cancers, with further results expected in Q1 2026.
- Safety Confirmation: Six patients across Cohorts 1, 2, and 3 have successfully completed treatment with GTB-3650, establishing the therapy's safety profile at escalating doses without any dose-limiting toxicities, thereby enhancing confidence in the clinical trial.
- Dose Escalation Plan: The trial is designed to include seven cohorts, with plans to enroll two patients per cohort, escalating doses from 1.25μg/kg/day to potentially 100μg/kg/day, demonstrating the company's ongoing commitment to efficacy and patient care.
- Therapeutic Prospects: GT Biopharma is also advancing GTB-5550, with regulatory submission for human trials expected in late December 2025 or January 2026, further expanding its market opportunities in cancer treatment.
See More
